Emular's medical world model predicts how treatments shape patient trajectories — guiding which drug to advance and which trial to run.
Selection decides the trial — and nothing predicts a drug's real effect before the trial runs. So most of the money finds nothing.
Four capabilities, one causal engine trained on real-world evidence.
Correlation predicts risk — the sickest get the drug, so disease drives the outcome. Emular reasons drug → target → pathway → outcome to isolate the drug's true effect.
Millions of longitudinal patient trajectories give the model the statistical power to see how treatments actually play out — far beyond any single trial.
Specify a protocol and Emular emulates its likely readout — endpoints, population, dose — so you can lock the design most likely to succeed before spending on the real one.
Every prediction is validated against randomised-controlled-trial outcomes — the gold standard — so results carry evidence, not just confidence.
The world model traces each causal link so a drug's effect is separated from the reason it was prescribed.
From a single protocol to a full portfolio — priced to the decision it de-risks.
Lock the protocol most likely to succeed — endpoints, population and dose, emulated before you commit.
Benchmark a candidate's pivotal trial before you sign — an independent read on the asset you're about to back.
Score every asset on one model, continuously — the whole pipeline ranked and re-ranked as evidence arrives.
We would be pleased to discuss our AI patient simulation platform, research collaborations, investment opportunities, or early access.
Please include your organisation and a brief description of what you would like to discuss. We normally reply within two business days.
Contact us